

Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1-2 (Cancelled).

3 (Currently amended). A transgenic mouse having integrated in its genome a nucleic acid construct according to ~~claim 1~~, comprising a mammalian T-cell lineage specific ~~expression regulatory sequence promoter~~ operably linked to a mammalian Glucocorticoid Induced Leucine-Zipper (GILZ) GILZ cDNA sequence, wherein said mouse expresses ~~GILZ~~ GILZ in its T-cell lineage at an elevated level compared to a non-transgenic mouse and ~~wherein the expression of GILZ results in an alteration of the thymocyte subset composition and of caspase 3 activation.~~

4 (Currently amended). The transgenic mouse according to claim 3, wherein said mammalian T-cell lineage specific ~~expression regulatory sequence promoter~~ comprises a human CD2 promoter and a human CD2 locus control region.

Claims 5-16 (Cancelled).

17(Original). A method for screening compounds having glucocorticoid-related effects, comprising:

administering a potential candidate compound to a transgenic mouse of claim 3, and to a control non-transgenic mouse; and

determining whether said potential candidate compound exhibits glucocorticoid-related effects by comparing the effects of the administration of said potential candidate to said transgenic mouse and to said control non-transgenic mouse.

18(Original). A method for screening compounds having glucocorticoid-related effects, comprising:

administering a potential candidate compound to a transgenic mouse of claim 4, and to a control non-transgenic mouse; and

determining whether said potential candidate compound exhibits glucocorticoid-related effects by comparing the effects of the administration of said potential candidate to said transgenic mouse and to said control non-transgenic mouse.

19(Currently amended). A method of producing a transgenic mouse whose genome comprises a nucleic acid construct, wherein said construct comprises a mammalian T-cell lineage specific, ~~expression regulatory sequence~~ promoter operably linked

to a mammalian Glucocorticoid Induced leucine-Zipper (GILZ) ~~GILR~~ cDNA sequence, said method comprising:

transferring a nucleic acid construct ~~according to~~
~~claim 1~~, comprising a mammalian T-cell lineage specific promoter
operably linked to a ~~GILR~~ mammalian GILZ cDNA sequence to a
fertilized mouse oocyte;

allowing the zygote resulting from the fertilized mouse
oocyte to develop to term, thereby obtaining a transgenic mouse
whose genome comprises the nucleic acid construct;

breeding said transgenic mouse with a non-transgenic
mouse to generate offspring; and

selecting from the offspring a transgenic mouse whose
genome comprises the nucleic acid construct, wherein said
transgenic mouse expresses GILR in the T-cell lineage at an
elevated level compared to a non-transgenic mouse.

Claim 20 (Cancelled).